Retatrutide (often abbreviated as “RETA”) is a synthetic peptide being studied as a triple receptor agonist, targeting:

• Glucagon-like peptide-1 (GLP-1) receptors

• Glucose-dependent insulinotropic polypeptide (GIP) receptors

• Glucagon receptors

By acting on all three pathways, retatrutide is designed to influence multiple aspects of metabolic regulation.

Research suggests it may:

• Enhance insulin secretion and improve glucose control

• Reduce appetite and caloric intake

• Increase energy expenditure via glucagon receptor activity

• Support significant weight loss and fat reduction

• Influence lipid metabolism and overall metabolic health

This multi-receptor approach may provide broader metabolic effects compared to dual or single incretin-based peptides.

Retatrutide is intended for research and laboratory use only.